



4 July 2025

SECTION 708A CLEANSING NOTICE

dorsaVi (ASX:DVL) (**dorsaVi** or the **Company**), advises that it has issued 70,000,000 fully paid ordinary shares (**Shares**).

Section 708A Cleansing Notice

This notice is given by the Company under Section 708A(5)(e) of the Corporations Act 2001 (Cth) (**Corporations Act**).

The Company hereby confirms that:

- (a) it has issued 70,000,000 Shares without disclosure to investors under part 6D.2 of the Corporations Act;
- (b) the Company is providing this notice under paragraph 5(e) of Section 708A of the Corporations Act;
- (c) as at the date of this notice, the Company, as a disclosing entity under the Corporations Act, has complied with:
 - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - (ii) section 674 and 674A of the Corporation Act as it applies to the Company; and
- (d) as at the date of this notice, there is no excluded information of the type referred to in Sections 708A(7) and 708A(8) of the Corporations Act.

– ENDS –

This release has been authorised for lodgement to the ASX by the Board of Directors.

For further information about dorsaVi, please contact:

Company

Andrew Ronchi
Chief Executive Officer
T: +61 417 882 267
E: ar@dorsavi.com

About dorsaVi

dorsaVi Ltd (ASX:DVL) is an ASX company focused on developing innovative motion analysis device technologies for use in clinical applications, elite sports, and occupational health and safety. dorsaVi believes its wearable sensor technology enables, for the first time, many aspects of detailed human movement and position to be accurately captured, quantified and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours. dorsaVi's focus is on two major markets:

- **Workplace:** dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to OHS workplace design, equipment or methods based on objective evidence. dorsaVi works either directly with major corporations, or through an insurance company's customer base with the aim of reducing workplace compensation and claims. dorsaVi has been used by major corporations including Sodexo, London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Monash Health, Coles, Woolworths, Toll, Toyota, Orora (formerly Amcor) and BHP Billiton.
- **Clinical:** dorsaVi is transforming the management of patients with its clinical solutions (ViMove, ViMove2 and Professional Suite) which provide objective assessment, monitoring outside the clinic and immediate biofeedback. The clinical market is segmented into physical therapy (physiotherapists), hospital in the home and elite sports. Hospital in the home refers to the remote management of patients by clinicians outside of physical therapy (i.e. for orthopaedic conditions). Elite sports refer to the management and optimisation of athletes through objective evidence for decisions on return to play, measurement of biomechanics and immediate biofeedback to enable peak performance.

Further information is available at www.dorsavi.com